SUPREMO is a phase 3 randomised trial evaluating radiotherapy post-mastectomy for intermediate-risk breast cancer. 1688 patients were enrolled from 16 countries between 2006 and 2013. We report the results of central pathology review carried out for quality assurance.A single recut haematoxylin and eosin (H&E) tumour section was assessed by one of two reviewing pathologists, blinded to the originally reported pathology and patient data. Tumour type, grade and lymphovascular invasion were reviewed to assess if they met the inclusion criteria. Slides from potentially ineligible patients on central review were scanned and reviewed online together by the two pathologists and a consensus reached. A subset of 25 of these cases was double-reported independently by the pathologists prior to the online assessment.The major contributors to the trial were the UK (75

作者：J S, Thomas；A M, Hanby；N, Russell；G, van Tienhoven；K, Riddle；N, Anderson；D A, Cameron；J M S, Bartlett；T, Piper；C, Cunningham；P, Canney；I H, Kunkler

来源：Breast cancer research and treatment 2017 年 163卷 1期